Health Care [ 3/12 ] | Biotechnology [ 9/75 ]
NASDAQ | Common Stock
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections.
Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 31, 25 | -0.31 Decreased by -93.75% | -0.99 Increased by +68.84% |
| Nov 18, 25 | -1.23 Decreased by -623.53% | -0.15 Decreased by -720.00% |
| Aug 12, 25 | -1.89 Decreased by -626.92% | -0.18 Decreased by -950.00% |
| May 13, 25 | -0.11 Increased by +60.71% | -0.14 Increased by +21.43% |
| Mar 17, 25 | -0.16 Increased by +56.76% | -0.18 Increased by +11.11% |
| Nov 13, 24 | -0.17 Increased by +29.17% | -0.20 Increased by +15.00% |
| Aug 8, 24 | -0.26 Increased by +7.14% | -0.22 Decreased by -18.18% |
| May 14, 24 | -0.28 Decreased by -12.00% | -0.24 Decreased by -16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | N/A Decreased by N/A% | -7.96 B Decreased by -286.05 K% | - - |
| Sep 30, 25 | 0.00 Decreased by N/A% | -1.99 M Increased by +29.37% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -2.25 M Increased by +45.50% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -2.15 M Increased by +50.91% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -2.78 M Increased by +45.61% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.82 M Increased by +9.42% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.12 M Decreased by -19.64% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -4.38 M Decreased by -50.81% | Decreased by N/A% Decreased by N/A% |